v3.25.2
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Product Information [Line Items]        
Total net revenue $ 1,269,483 $ 2,397,652 $ 3,123,080 $ 4,804,043
Total operating loss (2,515,560) (2,087,798) (5,142,699) (4,033,028)
Non-operating income (expense), net (1,516,243) (17,062) (1,540,826) (29,975)
Net loss before income tax expense (4,031,803) (2,104,860) (6,683,525) (4,063,003)
Income tax expense (28,984) (5,419) (37,679) (9,091)
Net loss (4,060,787) (2,110,279) (6,721,204) (4,072,094)
Diagnostic R&D [Member]        
Product Information [Line Items]        
Total net revenue 4,038 6,923
Total operating loss (440,651) (453,895) (946,390) (896,494)
Laboratory Services [Member]        
Product Information [Line Items]        
Total net revenue [1] 1,269,483 2,393,614 3,123,080 4,797,120
Total operating loss (1,646,471) (2,535,285) (3,914,127) (5,272,284)
General Corporate Activities [Member]        
Product Information [Line Items]        
Total operating loss $ (1,697,921) $ (1,496,270) $ (3,405,262) $ (2,668,293)
[1] The majority of the decrease versus the prior year is primarily due to discontinuing certain unprofitable pathology services to focus on CyPath® Lung and other high-margin services.